Page 1729 - Williams Hematology ( PDFDrive )

1704 Part XI: Malignant Lymphoid Diseases Chapter 104: Mature T-Cell and Natural Killer Cell Lymphomas 1705

60. Greer JP, York JC, Cousar JB, et al: Peripheral T-cell lymphoma: A clinicopathologic 88. Fraga M, Brousset P, Schlaifer D, et al: Bone marrow involvement in anaplastic large
study of 42 cases. J Clin Oncol 2:788–798, 1984. cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic
61. Alomari A, Hui P, Xu M: Composite peripheral T-cell lymphoma not otherwise spec- significance. Am J Clin Pathol 103:82–89, 1995.
ified, and B-cell small lymphocytic lymphoma presenting with hemophagocytic lym- 89. Lazzeri D, Agostini T, Bocci G, et al: ALK-1-negative anaplastic large cell lymphoma
phohistiocytosis. Int J Surg Pathol 21:303–308, 2013. associated with breast implants: A new clinical entity. Clin Breast Cancer 11:283–296,
62. Kim H, Jacobs C, Warnke RA, et al: Malignant lymphoma with a high content of epithe- 2011.
lioid histiocytes: A distinct clinicopathologic entity and a form of so-called “Lennert’s 90. Lechner MG, Megiel C, Church CH, et al: Survival signals and targets for therapy in
lymphoma.” Cancer 41:620–635, 1978. breast implant-associated ALK—Anaplastic large cell lymphoma. Clin Cancer Res
63. Gaulard P, Bourquelot P, Kanavaros P, et al: Expression of the alpha/beta and gamma/ 18:4549–4559, 2012.
delta T-cell receptors in 57 cases of peripheral T-cell lymphomas. Identification of a 91. Said SM, Reynolds C, Jimenez RE, et al: Amyloidosis of the breast: Predominantly AL
subset of gamma/delta T-cell lymphomas. Am J Pathol 137:617–628, 1990. type and over half have concurrent breast hematologic disorders. Mod Pathol 26:232–238,
64. Knowles DM: Immunophenotypic and antigen receptor gene rearrangement analysis in 2013.
T cell neoplasia. Am J Pathol 134:761–785, 1989. 92. Morris SW, Kirstein MN, Valentine MB, et al: Fusion of a kinase gene, ALK, to a nucle-
65. Kim SJ, Yoon DH, Kang HJ, et al: Bortezomib in combination with CHOP as first-line olar protein gene, NPM, in non-Hodgkin’s lymphoma. Science 263:1281–1284, 1994.
treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, 93. Kadin ME: Anaplastic large cell lymphoma and its morphological variants. Cancer Surv
single-arm, phase 2 trial. Eur J Cancer 48:3223–3231, 2012. 30:77–86, 1997.
66. Kahl C, Leithauser M, Wolff D, et al: Treatment of peripheral T-cell lymphomas (PTCL) 94. Falini B: Anaplastic large cell lymphoma: Pathological, molecular and clinical features.
with high-dose chemotherapy and autologous or allogeneic hematopoietic transplanta- Br J Haematol 114:741–760, 2001.
tion. Ann Hematol 81:646–650, 2002. 95. Rimokh R, Magaud JP, Berger F, et al: A translocation involving a specific breakpoint
67. Sibon D, Fournier M, Briere J, et al: Long-term outcome of adults with systemic (q35) on chromosome 5 is characteristic of anaplastic large cell lymphoma (“Ki-1 lym-
anaplastic large-cell lymphoma treated within the Groupe d’Etude des Lymphomes de phoma”). Br J Haematol 71:31–36, 1989.
l’Adulte trials. J Clin Oncol 30:3939–3946, 2012. 96. Shin S, Kim J, Yoon SO, et al: ALK-positive anaplastic large cell lymphoma with TPM3-
68. Frizzera G, Moran EM, Rappaport H: Angio-immunoblastic lymphadenopathy with ALK translocation. Leuk Res 36:e143–e145, 2012.
dysproteinaemia. Lancet 1:1070–1073, 1974. 97. Ma Z, Cools J, Marynen P, et al: Inv(2)(p23q35) in anaplastic large-cell lymphoma
69. Smith JL, Hodges E, Quin CT, et al: Frequent T and B cell oligoclones in histologically induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation
and immunophenotypically characterized angioimmunoblastic lymphadenopathy. Am by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis. Blood
J Pathol 156:661–669, 2000. 95:2144–2149, 2000.
70. Willenbrock K, Roers A, Seidl C, et al: Analysis of T-cell subpopulations in T-cell non 98. Hernandez L, Pinyol M, Hernandez S, et al: TRK-fused gene (TFG) is a new partner of
-Hodgkin’s lymphoma of angioimmunoblastic lymphadenopathy with dysproteinemia ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK
type by single target gene amplification of T cell receptor-beta gene rearrangements. translocations. Blood 94:3265–3268, 1999.
Am J Pathol 158:1851–1857, 2001. 99. Lamant L, Dastugue N, Pulford K, et al: A new fusion gene TPM3-ALK in anaplastic
71. Weiss LM, Strickler JG, Dorfman RF, et al: Clonal T-cell populations in angioimmuno- large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood 93:3088–3095,
blastic lymphadenopathy and angioimmunoblastic lymphadenopathy-like lymphoma. 1999.
Am J Pathol 122:392–397, 1986. 100. Cools J, Wlodarska I, Somers R, et al: Identification of novel fusion partners of ALK,
72. Feller AC, Griesser H, Schilling CV, et al: Clonal gene rearrangement patterns correlate the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory
with immunophenotype and clinical parameters in patients with angioimmunoblastic myofibroblastic tumor. Genes Chromosomes Cancer 34:354–362, 2002.
lymphadenopathy. Am J Pathol 133:549–556, 1988. 101. Touriol C, Greenland C, Lamant L, et al: Further demonstration of the diversity of
73. Attygalle A, Al-Jehani R, Diss TC, et al: Neoplastic T cells in angioimmunoblastic T-cell chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing
lymphoma express CD10. Blood 99:627–633, 2002. ALK kinase fused to CLTCL (clathrin chain polypeptide-like). Blood 95:3204–3207,
74. Yu H, Shahsafaei A, Dorfman DM: Germinal-center T-helper-cell markers PD-1 and 2000.
CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lym- 102. Krenacs L, Wellmann A, Sorbara L, et al: Cytotoxic cell antigen expression in anaplastic
phoma. Am J Clin Pathol 131:33–41, 2009. large cell lymphomas of T- and null-cell type and Hodgkin’s disease: Evidence for dis-
75. Dorfman DM, Brown JA, Shahsafaei A, et al: Programmed death-1 (PD-1) is a marker tinct cellular origin. Blood 89:980–989, 1997.
of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J 103. Foss HD, Anagnostopoulos I, Araujo I, et al: Anaplastic large-cell lymphomas of T-cell
Surg Pathol 30:802–810, 2006. and null-cell phenotype express cytotoxic molecules. Blood 88:4005–4011, 1996.
76. de Leval L, Rickman DS, Thielen C, et al: The gene expression profile of nodal peripheral 104. Lamant L, de Reynies A, Duplantier MM, et al: Gene-expression profiling of systemic
T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell anaplastic large-cell lymphoma reveals differences based on ALK status and two dis-
lymphoma (AITL) and follicular helper T (TFH) cells. Blood 109:4952–4963, 2007. tinct morphologic ALK+ subtypes. Blood 109:2156–2164, 2007.
77. Schlegelberger B, Zwingers T, Hohenadel K, et al: Significance of cytogenetic findings 105. Salaverria I, Bea S, Lopez-Guillermo A, et al: Genomic profiling reveals different
for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell
lymphadenopathy type. J Clin Oncol 14:593–599, 1996. lymphomas. Br J Haematol 140:516–526, 2008.
78. Siegert W, Agthe A, Griesser H, et al: Treatment of angioimmunoblastic lymphadenop- 106. Massimino M, Gasparini M, Giardini R: Ki-1 (CD30) anaplastic large-cell lymphoma in
athy (AILD)-type T-cell lymphoma using prednisone with or without the COPBLAM/ children. Ann Oncol 6:915–920, 1995.
IMVP-16 regimen. A multicenter study. Kiel Lymphoma Study Group. Ann Intern Med 107. Brugieres L, Deley MC, Pacquement H, et al: CD30(+) anaplastic large-cell lymphoma
117:364–370, 1992. in children: Analysis of 82 patients enrolled in two consecutive studies of the French
79. Takemori N, Kodaira J, Toyoshima N, et al: Successful treatment of immunoblastic Society of Pediatric Oncology. Blood 92:3591–3598, 1998.
lymphadenopathy-like T-cell lymphoma with cyclosporin A. Leuk Lymphoma 35:389–395, 108. Laver JH, Kraveka JM, Hutchison RE, et al: Advanced-stage large-cell lymphoma in
1999. children and adolescents: Results of a randomized trial incorporating intermediate-
80. Gerlando Q, Barbera V, Ammatuna E, et al: Successful treatment of angioimmunoblas- dose methotrexate and high-dose cytarabine in the maintenance phase of the APO
tic lymphadenopathy with dysproteinemia-type T-cell lymphoma by combined metho- regimen: A Pediatric Oncology Group phase III trial. J Clin Oncol 23:541–547, 2005.
trexate and prednisone. Haematologica 85:880–881, 2000. 109. Zinzani PL, Martelli M, Magagnoli M, et al: Anaplastic large cell lymphoma Hodgkin’s-
81. Quintini G, Iannitto E, Barbera V, et al: Response to low-dose oral methotrexate and like: A randomized trial of ABVD versus MACOP-B with and without radiation therapy.
prednisone in two patients with angio-immunoblastic lymphadenopathy-type T-cell Blood 92:790–794, 1998.
lymphoma. Hematol J 2:393–395, 2001. 110. Moskowitz AJ, Lunning MA, Horwitz SM: How I treat the peripheral T-cell lympho-
82. Tokunaga T, Shimada K, Yamamoto K, et al: Retrospective analysis of prognostic factors mas. Blood 123:2636–2644, 2014.
for angioimmunoblastic T-cell lymphoma: A multicenter cooperative study in Japan. 111. Foyil KV, Bartlett NL: Brentuximab vedotin and crizotinib in anaplastic large-cell lym-
Blood 119:2837–2843, 2012. phoma. Cancer J 18:450–456, 2012.
83. Falini B, Bigerna B, Fizzotti M, et al: ALK expression defines a distinct group of T/null 112. Gambacorti-Passerini C, Messa C, Pogliani EM: Crizotinib in anaplastic large-cell lym-
lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol phoma. N Engl J Med 364:775–776, 2011.
153:875–886, 1998. 113. Suzuki R, Kagami Y, Takeuchi K, et al: Prognostic significance of CD56 expression for
84. Pulford K, Lamant L, Morris SW, et al: Detection of anaplastic lymphoma kinase (ALK) ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell pheno-
and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic type. Blood 96:2993–3000, 2000.
cells with the monoclonal antibody ALK1. Blood 89:1394–1404, 1997. 114. Ferreri AJ, Govi S, Pileri SA, et al: Anaplastic large cell lymphoma, ALK-negative. Crit
85. Miranda RN, Aladily TN, Prince HM, et al: Breast implant-associated anaplastic large- Rev Oncol Hematol 85:206–215, 2013.
cell lymphoma: Long-term follow-up of 60 patients. J Clin Oncol 32:114–120, 2014. 115. Rassidakis GZ, Sarris AH, Herling M, et al: Differential expression of BCL-2 family
86. Xu J, Wei S: Breast implant-associated anaplastic large cell lymphoma: Review of a dis- proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-
tinct clinicopathologic entity. Arch Pathol Lab Med 138:842–846, 2014. cell lineage. Am J Pathol 159:527–535, 2001.
87. Gascoyne RD, Aoun P, Wu D, et al: Prognostic significance of anaplastic lymphoma 116. Delabie J, Holte H, Vose JM, et al: Enteropathy-associated T-cell lymphoma: Clinical
kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood and histological findings from the international peripheral T-cell lymphoma project.
93:3913–3921, 1999. Blood 118:148–155, 2011.

Kaushansky_chapter 104_p1693-1706.indd 1704 9/21/15 12:48 PM